Atlas Trials

Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer

Clinical trial NCT05547737 · UNKNOWN

Trial details

NCT number
NCT05547737
Sponsor
Henan Cancer Hospital
Status
UNKNOWN
Study type
OBSERVATIONAL
NSCLC
Start date
2022-09-21
Primary completion
2025-09-21
Enrollment
500

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.